NASDAQ:RTRX Travere Therapeutics (RTRX) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free RTRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.12▼$5.5050-Day Range$24.25▼$28.1852-Week Range$8.98▼$24.96Volume1.49 million shsAverage Volume412,277 shsMarket Capitalization$275.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Travere Therapeutics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Travere Therapeutics Stock (NASDAQ:RTRX)Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Read More Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. RTRX Stock News HeadlinesApril 17, 2024 | markets.businessinsider.comCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To KnowFebruary 23, 2024 | realmoney.thestreet.comTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. February 23, 2024 | msn.comTravere Therapeutics gains as EU backs kidney disease therapyFebruary 21, 2024 | msn.comNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?February 17, 2024 | realmoney.thestreet.comTravere Therapeutics price target raised by $4 at Citi, here's whyFebruary 16, 2024 | markets.businessinsider.comTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market CompetitionFebruary 14, 2024 | benzinga.comEarnings Preview For Travere TherapeuticsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. January 11, 2024 | markets.businessinsider.comTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market ProspectsDecember 7, 2023 | markets.businessinsider.comOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic ReorganizationDecember 6, 2023 | msn.comTravere (TVTX) Up on Latest Portfolio Updates & ReorganizationDecember 5, 2023 | markets.businessinsider.comBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic ReorganizationDecember 5, 2023 | realmoney.thestreet.comTravere Therapeutics upgraded to Buy from Neutral at CitiDecember 4, 2023 | marketwatch.comTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsNovember 21, 2023 | benzinga.comTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 8, 2023 | markets.businessinsider.comPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere TherapeuticsNovember 6, 2023 | benzinga.comPreview: Travere Therapeutics's EarningsOctober 31, 2023 | morningstar.comTravere Therapeutics Inc Ordinary Shares TVTXSeptember 30, 2023 | msn.comWedbush Reiterates Travere Therapeutics (TVTX) Outperform RecommendationSeptember 22, 2023 | msn.comWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-LowSeptember 21, 2023 | msn.comWhy Shares of Travere Therapeutics Are Slumping ThursdaySeptember 21, 2023 | markets.businessinsider.comBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, ChallengesAugust 31, 2023 | markets.businessinsider.comBank of America Securities Remains a Buy on Travere Therapeutics (TVTX)July 19, 2023 | marketwatch.comMirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere TherapeuticsJune 26, 2023 | benzinga.comTVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities LawsMay 3, 2023 | msn.comEvercore ISI Group Maintains Travere Therapeutics (TVTX) Outperform RecommendationSee More Headlines Receive RTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTRX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879FaxN/AEmployees221Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,430,000.00 Net Margins-49.13% Pretax MarginN/A Return on Equity-36.38% Return on Assets-14.90% Debt Debt-to-Equity Ratio0.66 Current Ratio7.23 Quick Ratio7.14 Sales & Book Value Annual Sales$175.34 million Price / Sales1.57 Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book1.05Miscellaneous Outstanding Shares51,052,000Free FloatN/AMarket Cap$275.17 million OptionableNot Optionable Beta0.67 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesEric DubePresident, Chief Executive Officer & DirectorLaura M. ClagueChief Financial & Accounting OfficerBill RoteSenior VP, Head-Research & DevelopmentNoah L. RosenbergChief Medical OfficerElizabeth E. ReedSecretary, Senior Vice President & General CounselKey CompetitorsKamadaNASDAQ:KMDANeoleukin TherapeuticsNASDAQ:NLTXErascaNASDAQ:ERASVerrica PharmaceuticalsNASDAQ:VRCAContineum TherapeuticsNASDAQ:CTNMView All Competitors RTRX Stock Analysis - Frequently Asked Questions How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:RTRX) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL). This page (NASDAQ:RTRX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
